In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
INDICATIONS:Metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy; unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; advanced renal cell carcinoma with prior anti-angiogenic therapy; Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin; head and neck cancer; colon cancer; liver cancer
In a review (May 2021) of the adverse reactions associated with nivolumab and ipilimumab, respectively, Health Canada concluded that there may be a link between nivolumab used alone or in combination with ipilimumab and the risks of autoimmune hemolytic anemia, aplastic anemia, cytokine release syndrome and tumor lysis syndrome.
The Canadian product safety information (Canadian Product Monograph) for nivolumab has been updated to include a warning for the risk of autoimmune hemolytic anemia. Health Canada is working with the manufacturer of nivolumab to also include the risks of aplastic anemia, cytokine release syndrome, and tumor lysis syndrome in the Canadian Product Monograph (CPM).
Please login to view the rest of this drug profile.